Head & Neck Cancers | Specialty

FDA Grants Fast Track Status to Eftilagimod Alpha for Frontline Recurrent/Metastatic Head and Neck Cancer

April 8th 2021

The FDA has granted a fast track designation to the soluble LAG-3 protein eftilagimod alpha for use in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

FDA Approves New Cetuximab Dose in KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck Cancer

April 7th 2021

The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

Dr. Cohen on the Goals of the SPEARHEAD-2 Trial in Head and Neck Cancer

March 30th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.

Tipifarnib Showcases Encouraging Efficacy in Relapsed or Metastatic HRAS-Mutant HNSCC

March 26th 2021

Tipifarnib showed promising clinical activity in patients with recurrent and/or metastatic, HRAS-mutant head and neck squamous cell carcinoma whose disease had progressed after prior therapy.

Rolling Submission for Toripalimab Started for Nasopharyngeal Carcinoma

March 4th 2021

The filing of a biologics license application has been initiated with the FDA for toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Breakthrough Therapy Designation to Tipifarnib for HRAS-Mutated HNSCC

February 24th 2021

February 24, 2021 - The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Treating BRAF V600 and NTRK Gene Fusion Positivity

February 11th 2021

The Future of RAI-Refractory DTC Management

February 11th 2021

Frontline Durvalumab Fails to Improve OS in Recurrent or Metastatic HNSCC

February 5th 2021

February 5, 2021 - Durvalumab failed to improve overall survival over the EXTREME chemotherapy regimen in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with tumors expressed high levels of PD-L1, missing a primary end point of the phase 3 KESTREL trial.

Rationale for Sequencing in Second Line

February 4th 2021

LIBRETTO-001 Phase 1/2 Trial Overview

February 4th 2021

Advice for Managing RAI-Refractory DTC

January 28th 2021

Molecular Testing in Treatment Selection

January 28th 2021

Search Continues for Agents to Provide Additive Benefit to Chemoradiation in Head and Neck Cancer

January 21st 2021

Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.

Sorafenib and Lenvatinib Side Effect Profile and Dosing

January 21st 2021

RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

January 21st 2021

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

January 18th 2021

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Multidisciplinary Management for the Treatment of DTC

January 18th 2021

Approaching Treatment of Low-Volume DTC

January 18th 2021